Pfenex (NASDAQ:PFNX) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Tuesday, BidAskClub reports.
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Pfenex in a report on Monday, October 28th.
Shares of PFNX traded down $0.11 during mid-day trading on Tuesday, hitting $13.56. 1,581 shares of the company traded hands, compared to its average volume of 324,701. Pfenex has a 1-year low of $3.40 and a 1-year high of $13.70. The firm’s 50 day simple moving average is $11.57.
Pfenex (NASDAQ:PFNX) last released its earnings results on Thursday, November 7th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $15.25 million during the quarter, compared to analyst estimates of $14.80 million.
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
See Also: Municipal Bonds
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.